Chemotherapy-Induced Peripheral Neuropathy



Chemotherapy-induced peripheral neuropathy (CIPN) is often defined as a side effect brought on by damage to the peripheral nerves caused by exposure to a chemotherapeutic agent. Chemotherapy-induced peripheral neuropathy (CIPN) is a very common side effect of chemotherapy. Its prevalence varies from 19% to over 85%. The symptoms are mostly from sensory neuropathy that may be accompanied by motor and autonomic dysfunction. With more effective chemotherapy, cancer survival is increasing, but the incidence of chemo-induced neuropathy has emerged as a major problem both for cancer survivors and treating physicians. The pathophysiology is variable and poorly understood. There is no single effective method of preventing CIPN, and the options of treating this condition are very limited. There are six main substance groups that cause damage to peripheral sensory, motor, and autonomic neurons, which result in the development of CIPN: platinum-based antineoplastic agents, vinca alkaloids, epothilones (ixabepilone), taxanes, proteasome inhibitors (bortezomib), and immunomodulatory drugs (thalidomide). Onset of symptoms is variable usually few weeks to months after the therapy is started. Usually its doses are related and can be severe enough for patient to opt out of live saving chemotherapy. With prevalence up to 85%, it is a major medical issue.


Chemotherapy-induced peripheral neuropathy Peripheral neuropathy induced by chemotherapy Neuropathy induced by chemotherapy Scrambler therapy for chemotherapy-induced peripheral neuropathy Neuromodulation for peripheral neuropathy 


  1. 1.
    Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, Cheung YT, Steer C, Storey DJ, Chandwani KD, Paice J. Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2014;22(8):2281–95.CrossRefGoogle Scholar
  2. 2.
    Fehrenbacher JC. Chemotherapy-induced peripheral neuropathy. InProgress in molecular biology and translational science, vol. 131: Academic Press; 2015. p. 471–508.Google Scholar
  3. 3.
    Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40(7):872–82.CrossRefGoogle Scholar
  4. 4.
    Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol. 2016;140(1):176–83.CrossRefGoogle Scholar
  5. 5.
    Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology. 2012;14(suppl_4):iv45–54.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, Nolano M, Merkies IS, Polydefkis M, Smith AG, Sommer C. European Federation of Neurological Societies/peripheral nerve society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the peripheral nerve society. Eur J Neurol. 2010;17(7):903–e49.CrossRefGoogle Scholar
  7. 7.
    Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772–81.CrossRefGoogle Scholar
  8. 8.
    Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90–107.CrossRefGoogle Scholar
  9. 9.
  10. 10.
    Smith EM, Pang H, Cirrincione C, Fleishman S, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a ramdomized clinical trial. JAMA. 2013;309(13):1359–67.CrossRefGoogle Scholar
  11. 11.
    Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, Lachance DH, Liu H, Shelerud RA, Cheville AL, Loprinzi CL. Pilot evaluation of scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2015;23(4):943–51.CrossRefGoogle Scholar
  12. 12.
    Munch J. Managing chemotherapy-induced neuropathy. MD Anderson Cancer Center. Available from:
  13. 13.
    Prinsloo S, Novy D, Driver L, Lyle R, Ramondetta L, Eng C, McQuade J, Lopez G, Cohen L. Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: a pilot study. Cancer. 2017;123(11):1989–97.CrossRefGoogle Scholar
  14. 14.
    Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(818):1941–67.CrossRefGoogle Scholar
  15. 15.
    Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis, PAIN®. 2014;155(12):2461–70.Google Scholar
  16. 16.
    Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, Fung C, Janelsins MC, Asare M, Lin PJ, Reddy PS. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018;26(4):1019–28.CrossRefGoogle Scholar
  17. 17.
    Boyette-Davis JA, Walters ET, Dougherty PM. Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain Manag. 2015;5(4):285–96.CrossRefGoogle Scholar
  18. 18.
    Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419–37.CrossRefGoogle Scholar
  19. 19.
    Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27–46.CrossRefGoogle Scholar
  20. 20.
  21. 21.

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Anesthesiology and Critical CareUniversity of ChicagoChicagoUSA
  2. 2.Department of Anesthesia and Critical CareUniversity of ChicagoChicagoUSA

Personalised recommendations